DLX105-DMP / DelArrivo - LARVOL DELTA

A Study of DLX105-DMP in Subjects With Plaque Psoriasis (clinicaltrials.gov) - P1 | N=10 | Completed | Sponsor: DelArrivo, Inc. | Recruiting ➔ Completed | Phase classification: P1/2 ➔ P1 | N=18 ➔ 10

Enrollment change • Phase classification • Trial completion • Dermatology • Immunology • Psoriasis

A Study of DLX105-DMP in Subjects With Plaque Psoriasis (clinicaltrials.gov) - P1/2; N=18; Recruiting; Sponsor: DelArrivo, Inc.; Not yet recruiting ➔ Recruiting; N=12 ➔ 18; Trial completion date: Nov 2021 ➔ Mar 2022; Trial primary completion date: Nov 2021 ➔ Mar 2022

Clinical • Enrollment change • Enrollment open • Trial completion date • Trial primary completion date • Dermatology • Immunology • Psoriasis

A Study of DLX105-DMP in Subjects With Plaque Psoriasis (clinicaltrials.gov) - P1/2; N=12; Not yet recruiting; Sponsor: DelArrivo, Inc.; Trial completion date: Jul 2021 ➔ Nov 2021; Trial primary completion date: Jul 2021 ➔ Nov 2021

Clinical • Trial completion date • Trial primary completion date • Dermatology • Immunology • Psoriasis

A Study of DLX105-DMP in Subjects With Plaque Psoriasis (clinicaltrials.gov) - P1/2; N=12; Not yet recruiting; Sponsor: DelArrivo, Inc.; N=20 ➔ 12; Trial completion date: Sep 2020 ➔ Jul 2021; Trial primary completion date: Sep 2020 ➔ Jul 2021

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Dermatology • Immunology • Psoriasis